Future research into therapies blocking the pro-inflammatory cytokines IL-6 and sTNF-αR1 in hip fracture patients may provide an intervention which influences the development of depression or depressive symptoms after hip fracture. The gene discussed is IL6; the disease is depressive symptom measurement.